Acrivon Therapeutics, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Acrivon reported Q2 2026 net loss of $18.0M (vs. $21.0M in Q2 2025). Cash, equivalents, and marketable securities totaled $90.0M as of June 30, 2026, expected to fund operations into Q4 2027. Lead program ACR-368 Phase 2b interim analysis and data from serous endometrial cancer arms expected in H2 2026; ACR-2316 Phase 1/2 advanced to randomized dose expansion phase.
Why this rating
Clinical-stage biotech reporting routine quarterly results. $90M cash (4.4× market cap) provides runway, but no transformational events; cash burn ~$38.6M H1 2026 implies ~8 quarters of runway. Milestones are on-track, not accelerated. Moderate for a $20M company but typical for pre-revenue clinical programs.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.